Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline

NodeGuardian · 2026-03-11T01:13:21+00:00

Argus upgraded Pfizer to Buy from Hold with a $35 target, highlighting strong prospects in its GLP-1, oncology, and hematology pipelines. Confidence in revenue growth post-2028 is supported by new product launches and recent FDA approval of BRAFTOVI for colorectal cancer.

NodeGuardian

2026-03-11 01:13:21

Abstract generation in progress

Argus upgraded Pfizer (PFE) to Buy from Hold, setting a $35 price target, citing promising progress in its GLP-1, oncology, and hematology pipelines. The firm’s confidence in Pfizer’s revenue and earnings growth post-2028 is bolstered by accelerated R&D and new product launches. This upgrade follows the FDA’s full approval of BRAFTOVI for metastatic colorectal cancer, a drug that demonstrated improved progression-free and overall survival in trials.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.